CD69 to CD3 ratio of peripheral blood mononuclear cells as a marker to monitor systemic lupus erythematosus disease activity

Abstract

CD69 is an early T cell activation marker. In order to investigate whether the disease activity of systemic lupus erythematosus (SLE) is correlated with T cell hyperactivity as well as B cell hyperactivity, we measured the CD69 to CD3 ratio (CD69/CD3) of peripheral blood mononuclear cells (PBMCs) from 42 SLE patients and 18 healthy controls. To assess B cell activation, we measured the levels of anti-dsDNA, complement C3 and C4. Disease activity was assessed with the SLE disease activity index (SLEDAI) score. The mean value (± standard deviation) of CD69/CD3 for SLE patients (3.34 ± 0.486) and healthy controls (0.92 ± 0.015) were significantly different (P < 0.05). CD69/CD3, anti-dsDNA, C3 and C4 were all significantly correlated with SLEDAI (r = 0.50, 0.51, -0.68, -0.31, respectively, P < 0.05). CD69/CD3 could explain 25.4% of the variance in SLEDAI, and 6.7% of the variance that was independent of anti-dsDNA, C3 and C4. In patients with SLEDAI scores which were discordant with anti-dsDNA, C3 and C4 values, CD69/ CD3 still showed high correlation with SLEDAI. We conclude that CD69/CD3, which detects T cell activation, is correlated with SLEDAI scores. Thus, T cell activation contributes part of the disease activity independent of B cell activity. This marker can complement in the estimation of disease activity when levels of anti-dsDNA, C3 and C4 fail to show good correlation.

Keywords

CD69 CD3 systemic lupus erythematosus SLEDAI

Get full access to this article

View all access options for this article.

References

Lanier LL et al. Interleukin 2 activation of natural killer cells rapidly induces the expression and phosphorylation of the Leu-23 antigen. J Exp Med 1988; 167: 1572-1585.

Cosulich ME et al. Functional characterization of an antigen involved in an early step of T-cell activation. Proc Natl Acad Sci USA 1987; 884: 4205-4209.

Yesti R. , Phillips JH , Lanier LL Constitutive expression of phosphorylated activation antigen (Leu 23) by CD3 bright human thymocytes. J Immunol 1988; 141: 2557-2563.

Gavioli R. et al. CD69 molecule in human neutrophils: its expression and role in signal-transducing mechanism. Cell Immunol 1992; 142: 186-196.

Nishikawa K. et al. In vivo expression of CD69 on lung eosinophils in eosinophilic pneumonia: CD69 as a possible activation marker for eosinophils . J Allergy Clin Immunol 1992 ; 90: 169-174.

Lopez-Cabrera M. et al. Molecular cloning, expression, and chromosomal localization of the human earliest lymphocyte activation antigen AIM/CD69, a new member of the c-type animal lectin superfamily of signal-transmitting receptors. J Exp Med 1993; 178: 537-547.

Ziegler SG et al. The mouse CD69 gene, structure, expression, and mapping to the NK gene complex. J Immunol 1994; 152: 1228-1236.

Testi R. , Phillips JH , Lanier LL T cell activation via Leu-23 (CD69). J Immunol 1989; 143: 1123-1128.

Sanchez-Mateos P. , Sanchez-Madrid F. Structure function relationship and immunochemical mapping of external and intracellular antigenic sites on the lymphocyte activation inducer molecule, AIM/CD69. Eur J Immunol 1991; 21: 2317-2325.

10.

Sakane T. et al. B cell hyperactivity and its relation to distinct clinical features and the degree of disease activity in patients with systemic lupus erythematosus . Arthritis Rheum 1988; 31: 80-87.

11.

Tan EM et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1272-1277.

12.

Bombardier C. et al. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-640.

13.

Schur PH , Sandson J. Immunological factors and clinical activity in lupus erythematosus . N Engl J Med 1968; 278: 533-538.

14.

Gladman DD , Urowitz MB , Keystone EC Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serologic feature. Am J Med 1979; 66: 210-215.

15.

Bluestein H. Neuropsychiatric disorders of SLE. In: Lahita RD (ed). Systemic Lupus Erythematosus. 2 edn. New York, John Wiley & Sons, 1992; pp 639-656.

16.

Al-Janadi M. , Raziuddin S. B cell hyperactivity is a function of T-cell-derived cytokines in systemic lupus erythematosus. J Rheumatol 1993; 20: 1888-1891.

17.

Spronk PE , Gun BT , Limburg PC , Kallenberg CG B cell activation in clinically quiescent systemic lupus erythematosus (SLE) is related to immunoglobulin levels, but not to levels of anti-ds DNA, not to concurrent T cell activation. Clin Exp Immunol 1993; 93: 39-44.

18.

Swaak AJ et al. Serum levels of soluble forms of T cell activation antigens CD27 and CD25 in systemic lupus erythematosus in relation with lymphocyte count and disease course. Clin Rheumatol 1995 ; 14: 293-300.